OOIR: Observatory of International Research

Papers

(The H4-Index of Cytotherapy is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)

Article	Citations
Critical considerations for the development of potency tests for therapeutic applications of mesenchymal stromal cell-derived small extracellular vesicles	142
Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial	94
Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: a randomized controlled study	67
Repeated subarachnoid administrations of allogeneic human umbilical cord mesenchymal stem cells for spinal cord injury: a phase 1/2 pilot study	60
Generating natural killer cells for adoptive transfer: expanding horizons	47
Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predisposition	45
Inducible secretion of IL-21 augments anti-tumor activity of piggyBac-manufactured chimeric antigen receptor T cells	38
Advances in generation of three-dimensional skin equivalents: pre-clinical studies to clinical therapies	38
Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States	37
The effects of intravenous infusion of autologous mesenchymal stromal cells in patients with subacute middle cerebral artery infarct: a phase 2 randomized controlled trial on safety, tolerability and	33
Pre-clinical investigation of mesenchymal stromal cell-derived extracellular vesicles: a systematic review	33
Current evidence on mesenchymal stem cell therapy for traumatic spinal cord injury: systematic review and meta-analysis	33
The NK-92 cell line—30 years later: its impact on natural killer cell research and treatment of cancer	31
Standardized xeno- and serum-free culture platform enables large-scale expansion of high-quality mesenchymal stem/stromal cells from perinatal and adult tissue sources	31
Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation	30
Challenges of manufacturing mesenchymal stromal cell–derived extracellular vesicles in regenerative medicine	30
Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing	29
Mechanism for the attenuation of neutrophil and complement hyperactivity by MSC exosomes	29
Cell-based therapies for coronavirus disease 2019: proper clinical investigations are essential	29
Ex vivo-expanded highly pure ABCB5+ mesenchymal stromal cells as Good Manufacturing Practice-compliant autologous advanced therapy medicinal product for clinical use: process validation and first in-h	29
Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19+ malignancy in a mouse model	28
Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products	26
Indirect co-culture of lung carcinoma cells with hyperthermia-treated mesenchymal stem cells influences tumor spheroid growth in a collagen-based 3-dimensional microfluidic model	25
Human mesenchymal stromal cells small extracellular vesicles attenuate sepsis-induced acute lung injury in a mouse model: the role of oxidative stress and the mitogen-activated protein kinase/nuclear	24